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We have shown previously that brain tissue contains protein kinases which can phosphorylate tau protein to a state reminiscent of the pathological 
state of Alzheimer paired helical filaments (PHFs); these include proline-directed kinases which phosphorylate SP or TP motifs (such as MAP kinase 
and GSK-3) [Drewes et al. (1992); Mandelkow et al. (1992)], as well as a novel kinase which phosphorylates S262 of tau protein and thereby strongly 
reduces the binding of tau to microtubules [Biemat et al. (1993)]. Here we report on the corresponding phosphatases in brain which normally keep 
the ‘pathological’ sites free of phosphate. The major phosphatases acting on tau are calcineurin and PP-2A, but not PP-1. Both are present and 
active in brain extracts, they can dephosphorylate recombinant au after prior phosphorylation with either MAP kinase, GSK-3, or brain extract, 
and the course of dephosphorylation can be monitored with antibodies diagnostic of the pathological state of tau. Both phosphatases also act directly 
on PHF tau isolated from Alzheimer brains. 
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1. INTRODUCTION 
Tau from Alzheimer paired helical filaments differs 
from normal tau by abnormal aggregation and an ab- 
normal state of phosphorylation ([16,38]; for reviews see 
[24,27,42]). In order to understand the origins of the 
disease it is of interest o clarify the causes of the abnor- 
mal phosphorylation, that is, the protein kinases and 
phosphatases acting on tau, and their regulation. We 
have previously identified two types of kinases which 
phosphorylate potentially pathological sites on tau, as 
well as their phosphorylation sites. The first type of 
kinases belongs to the family of proline-directed kinases 
(examples are MAP kinase and GSK-3); it induces the 
phosphorylation of SP and TP motifs in tau. This can 
be recognized by diagnostic antibodies which discrimi- 
nate between normal tau and PHF-tau, by an M, shift 
of the protein on SDS gels, and by phosphopeptide 
sequencing [4,10,30]. The second type of kinases phos- 
phorylates S262 (e.g. a new 35 kDa/41 kDa kinase) and 
thereby strongly decreases the interaction between tau 
and microtubules [5]. Both types of kinase are active in 
brain extracts obtained from normal or Alzheimer 
brains [17]. However, we noted previously that the 
phosphorylation by the brain extract becomes signifi- 
cant only when phosphatase inhibitors were added to 
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the extract. EGTA inhibits the Ca*‘-calmodulin de- 
pendent phosphatase calcineurin (alias PP-2B; [35]), 
while okadaic acid inhibits PP-1, PP-2A, and to a lesser 
extent calcineurin (IC% = 10 nM, 0.1 nM, 5 ,uM, respec- 
tively; [3,7]). We have now studied the effects of these 
phosphatases in more detail and conclude that cal- 
cineurin and PP-2A are both capable of removing both 
types of pathological phosphates from tau. These re- 
sults will be compared with other studies on the 
dephosphorylation of MAPS in vitro [13,14,31,39] and 
in situ [19]. 
2. MATERIALS AND METHODS 
Recombinant human isoform htau40 [12] was expressed in E. coli 
and purified as described [4]. Tau construct K18 was derived from 
htau40 and comprised the 4 microtubule binding repeats (residues 
Q244-E372; [5]. Tau from PHFs was prepared from brain tissue of 
Alzheimer patients following [15]. 
2.1. Kineses 
pp42 MAP kinase was prepared from porcine brain by sequential 
chromatography on Q-Sepharose, Superdex G-75 and Phenylsuperose 
FPLC essentially as described [lo]. 
2.2. Phosphatases 
PP-2A was prepared from rabbit skeletal muscle as described [21]. 
The specific activities of the phosphatase preparations were 2800 U/ 
mg for PP-ZA,,,, 2300 U/mg for PP-2AT72, 16,000 Ulmg for PP-2Au 
and 18,000 U/ml for the catalytic subunit of PP-1 (1 unit dephospho- 
rylates 1 mnol of “P-labeled phosphorylase/ min at 3O’C). Calcineurin 
(PP-2B) was prepared from bovine brain as described [23] with a 
specific activity of 15 U/mg (1 unit dephosphorylates 1 nmol of 32P- 
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labeled substrate peptide (1 PM) per min at 3O’C). PP-1 catalytic 
subunit was prepared according to DeGuzman and Lee [9]), inhibitors 
I-l and I-2 according to Waelkens et al. (371. 
2.3. Brain extracts 
In some experiments, phosphorylation and dephosphorylation were 
achieved by an extract of soluble proteins from brain. For phosphoryl- 
ation experiments, fresh brain tissue cleaned from meninges and blood 
vessels was homogenized at 0.2 g tissue per ml buffer (25 mM Tris- 
HCl, pH 8.0, containing 5 mM EGTA, 2 mM DTT, 0.2 mM Na;VO,, 
40 mM NaF, 10 PM okadaic acid, 1 mM PMSF, 10 &ml leupetin, 
10 &ml aprotinin, 10 &ml pepstatin, 0.03% Brij-35) and desalted 
over a disposable column (PDIO, Pharmacia) equilibrated in the same 
buffer. For dephosphorylation experiments, the extraction buffer was 
25 mM Tris-HCl, 2 mM DTT, 0.03% Brij-35 and protease inhibitors 
as above. 
2.4. Tau from PHFs 
PHFs were prepared after Greenberg and Davies [15]. The PHFs 
were solubilixed with 2 M yanidine thiocyanate for 2 h at 37°C then 
centrifuged at 100,000 xg. The supematant was dialyzed against 
water and lyophilized. For dephosphorylation assays the residual was 
dissolved in dephosphorylation buffer (see below) and incubated for 
5 h with 5 U/ml calcineurin or 20 U/ml PP-2A,,,. 
2.5. Antibodies 
Monoclonal antibody AT8 directed against Alzheimer PHFs was 
a gift from Dr. A. Vandevoorde (Innogenetics S.A., Gent, Belgium), 
mAb SMI31 and SMI-33 from Stemberger Monoclonals Inc. (Balti- 
more, MD, USA), and mAb Tau-1 was a gift from Dr. L. Binder 
(Univ. Alabama). 
2.6. Phosphorylation assays 
Recombinant htau40 (3 PM) was phosphorylated by 0.2-0.5 units 
of MAP kinase per ml (1 unit being the amount of kinase that catalyzes 
the phosphorylation of 1 nmol of htau40 per minute). The phosphoryl- 
ation buffer contained 40 mM HEPES, pH 7.2,0.2 mM PMSF, 1 mM 
DTT, 2 mM EGTA,, 5 mM MgCl,, and 2 mM [y-“P]ATP (specific 
activity adjusted to 40 Cilmol). After 16 h of incubation at 37”C, the 
buffer was changed to 25 mM Tris-HCl, pH 7.4, 0.1 mM DTT, 
0.1 mM PMSF (dephosphorylation buffer) by gel filtration on a 
G25-Superfine column (3.2 x 100 mm, Pharmacia). Protein concen- 
tration was determined by the BCA assay (Sigma) and incorporated 
radioactivity by Cerenkov counting of gel slices. 
2.7. Dephosphorylation assays 
32P-labelled htau40 (2.5 PM in the standard assay) was incubated 
with different amounts of phosphatase at 30°C in dephosphorylation 
buffer (0.5 mg/ml ovalbumin or bovine serum albumin (Serva) was 
added to prevent non-specific interactions). The individual conditions 
for the dephosphorylation experiments are indicated in the figure 
legends. The reaction was stopped by addition of sample aliquots to 
boiling SDS sample buffer. Samples were electrophoresed on 7-15% 
gradient gels, the tau bands excised after Coomassie staining and 
counted. Calcineurin was preincubated with 10 mM MgCl? and 
0.2 mM DTT at 3O’C for 10 min. Incubations with calcineurin con- 
tained always 1 mM CaCl,, 1 mM M&l, and 0.1 mg/ml calmodulin 
(Sigma). 
2.8. Nomenclature and abbreviations 
Phosphatase nomenclature: There are several names in use for the 
phosphatase PP-2A [6] alias PCS (for polycation stimulated phosphat- 
ase; [371). The enzyme occurs as a heterodimer or heterotrimer. The 
dimer consists of a 36 kDa catalytic subunit (C-subunit, PP-2&) and 
a 65 kDa regulatory subunit (A-subunit). The trimer has an additional 
third subunit (B-subunit) which is variable (e.g. 55,72 or 74 kDa). The 
enzymes used in this study are the two trimeric forms PP-2A,,, 
(= PCS-H = PP-2AJ and PP-2A,, (= PCS-M) and the dimeric form 
PP-2A, (= PCS-L = PP-2A3. 
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PP-1 [6] alias ATP, Mg-dependent phosphatase (AMD phosphat- 
ase; [371) consists of a 37 kDa catalytic subunit which may be com- 
plexed to regulatory subunits such as inhibitor-2 (whose phosphory- 
ation by the kinase GSK3 alias activating factor FA leads to the 
activation of the phosphatase). It is usually bound to a tissue-specific 
targeting subunit. In this study we have used the purified catalytic 
subunit, PP-1,. 
PP-2B alias calcineurin (for review see [35]) is a Ca-calmodulin 
activated phosphatase which consists of a 60 kDa catalytic subunit 
(A-subunit, CN-A) which is activated by binding of calmodulin, and 
a 19 kDa regulatory calmodulin-like subunit (CN-B). In this study we 
have used dimeric calcineurin and activated it with Ca” and calmod- 
ulin. 
PP-2A, = PCS-H = PP-2Ar,, = trimeric form with 55 kDa B-subunit 
(A + C + B, 35 + 65 + 55 kDa) 
PCS-M = PP-2AT1? = trimeric from with 72 kDa B”-sub- 
unit (A + C + B”, 36 + 65 + 72 kDa) 
PP-2Az = PCS-L = PP-2AD = dimeric form (A + C, 36 + 65 kDa) 
PP-2A, =. 36 kDa catalytic subunit of PP-2A 
PP-2B = calcineurin (active in the form CN-A + CN - B + 
calmodulin) 
Other abbreviations: DTT, dithiothreitol; EGTA, ethylene glycol- 
O,fY-bis(2-aminoethyl ether)-N,N,N’-tetraacetic a id; GSK-3, glyco- 
gen synthase kinase-3; MAP kinase, p42 mitogen activated protein 
kinase (alias ERK2); MAP, microtubule associated protein; PHF, 
paired helical filament; PMSF, phenyhnethylsulfonyl fluoride; OA, 
okadaic acid. 
3. RESULTS 
3.1. Tau phosphatase activity in the brain extract 
The findings reported here were initially triggered by 
the observation that an extract prepared from mammal- 
ian brain possesses a kinase activity towards tau that 
induces the Alzheimer-like antibody reactivity (by phos- 
phorylating mostly SP and TP motifs; [4,29]) and re- 
duces microtubule interactions by phosphorylating 
Se?2 [5]. But it was also clear that phosphatases played 
an important role since efficient phosphorylation was 
achieved only in the presence of phosphatase inhibitors 
[17]. The extract by itself allowed only minimal phos- 
phorylation (C 0.5 Pi incorporated into tau). With 5 mM 
EGTA (to block the Ca2+ dependent phosphatase cal- 
cineurin) the phosphorylation increased to = 4 Pi. 10 nM 
OA (to block PP-2A) had no effect, nor did 10 PM OA 
(to block both PP-2A and PP-1). However, with 5 mM 
EGTA and 10 ,uM OA combined a level of = 5 Pi was 
achieved, about 1 Pi more than with 5 mM EGTA 
alone. These data suggested that endogenous 
phosphatases, particularly calcineurin, were more po- 
tent than the endogenous kinases so that the Alzheimer- 
like phosphorylation of tau was prevented in normal 
brain extract. 
These earlier experiments were designed to explore 
phosphorylation but were not optimized for studying 
dephosphorylation. We therefore modified the proto- 
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Fig. 1. Dephosphorylation of htau40 with extract from porcine brain 
under various conditions as indicated below. Extract from porcine 
brain (5 ~1, total protein concentration adjusted to 1 mg/ml) was 
incubated at 30°C with 50 ~1 of htau40 (2.5 PM, phosphorylated with 
MAP kinase, 9.3 mol of “P incorporated per mol of tau). Aliquots 
were withdrawn at the indicated time intervals (0 min, 30 min, 60 min, 
5 h, 20 h), mixed with boiling SDS sample buffer, electrophoresed on 
7-15% polyacrylamide gels and processed for autoradiography. (A) 
Control: dephosphorylation of tau by the brain extract without any 
phosphatase inhibitors added. The dephosphorylation is rapid and 
complete in less than an hour. (B) Addition of 5 mM EGTA to inhibit 
calcineurin. Phosphate remains bound to tau for 20 h. (C) and (D) 
Addition of okadaic acid (an inhibitor of PP-1, PP-ZA, and PP-2B with 
I&, values of 10 nM, 0.1 nM, and 5 PM, respectively, see [7]). At 
2 nM OA there is no inhibition of phosphatase activity, at 20 PM it 
is substantial. (E) and (F) Addition of the inhibitors I-l and I-2 of PP-1 
at 0.2 /IM. There is no inhibition of phosphatase activity, showing that 
PP-1 is not responsible for dephosphorylating tau in the extract. 
col: we omitted ATP (to disable the kinases), and in- 
stead of using unphosphorylated recombinant tau as 
substrate we first phosphorylated it with purified MAP 
kinase (or GSK-3) and then observed its dephos- 
phorylation by the brain extract. In the absence of in- 
hibitors, dephosphorylation is nearly complete within 
30 min (Fig. lA), illustrating the presence of en- 
dogenous phosphatases. 5 mM EGTA inhibits the 
dephosphorylation completely (Fig. 1 B), indicating that 
calcineurin is a major phosphatase of tau in the extract. 
Okadaic acid fails to stop the dephosphorylation at a 
concentration of 2 nM (Fig. lC), but is an efficient 
inhibitor at 20 ,uM (Fig. 1D). Considering that the I&, 
values are 10 nM and 0.1 nM for PP-1 and PP-2A, this 
would argue superficially that PP-1 is the dominant 
phosphatase; however, this conclusion is not stringent 
since PP-2A concentrations are often too high so that 
nM OA does not s&lice to block all the enzyme (see 
[7,40]). In fact the experiments of Fig. 1E and F with the 
inhibitors I-l and I-2 of PP-1 show that blocking this 
phosphatase makes no difference to the dephosphoryla- 
tion of tau. These data leave calcineurin and PP-2A as 
two possible candidates. 
3.2. Dephosphorylation of tau by calcineurin and PP-2A 
The nest step was to test the individual phosphatases, 
and to see whether they freed up the abnormal phospho- 
rylation sites. Tau was pre-phosphorylated by MAP 
kinase to a level of -10 Pi/molecule. Phosphorylation 
by this kinase can be recognized by four features: (i) the 
amount of phosphate as measured by autoradiography, 
(ii) the nature of the phosphorylation sites (SP or TP 
motifs), (iii) the shift towards higher M, in the SDS gel, 
similar to the Alzheimer tau, (iv) the reaction with cer- 
tain antibodies whose epitopes are sensitive to phospho- 
rylation. Calcineurin reversed all of these changes (Fig. 2). 
The M, shifted down again (Fig. 2A) and the incor- 
porated phosphate disappeared (Fig. 2B). Significantly, 
the reaction with the PHF-specific antibodies disap- 
peared (e.g. AT& sensitive to phosphorylated S199 and/ 
or S202, or SM131 reacting with phosphorylated S396/ 
S404; [29]). Conversely the reactivity with antibodies 
recognizing unphosphorylated SP motifs reappeared 
(e.g. SM133 for unphosphorylated S235, or Tau-1 for 
unphosphorylated S 199/S202, Fig. 2C-E). This re- 
sponse is complementary to what one observes when 
tau is phosphorylated with proline-directed kinases 
such as MAP kinase or GSK-3. We conclude that cal- 
cineurin can dephosphorylate all SP and TP motifs of 
human tau which are targets of MAP kinase. 
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Fig. 2. (A) Time course of dephosphorylation of MAP kinase- 
phosphorylated htau40 with calcineurin monitored by gel shift and 
antibody response. “P-labeled hTau 40 (2.5 PM) containing 7.4 mol 
of phosphate per mole of tau was incubated with PP-2B (fhtal concen- 
tration 13O&nl, corresponding to 2 U/ml). Aliquots were withdrawn 
after the indicated time intervals and mixed with SDS sample buffer. 
(A) Coomassie stained SDS gradient gel (7-1596). Note the downward 
shift in the gel upon dephosphorylation. The weak and constant band 
below tau is BSA present in the calcmeurin sample. (B) Autoradi- 
ograph, showing the loss of phosphate. (C) Immunoblots of the same 
samples with PHF-specitic mAb AT-8, showing the loss of phosphate 
at S199/S202. (D) Immunoblot with mAB Tau-1, showing the appear- 
ance of the dephoshorylated epitope at S199/S202. (E) Immunoblot 
with mAb SM133, showing the appearance of dephosphorylated S235. 
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Fig. 3. (A) Time course of dephosphorylation of MAP kinase- 
phosphorylated Tau with PF2A,, as monitored by gel shift and anti- 
body response. ?-labeled hTau 40 (2.5 FM) was incubated with 
PP-ZA, (final concentration 10 @ml) and aliquots were withdrawn 
after the indicated time intervals and mixed with SDS sample buffer. 
(A) Coonmassie stained SDS gradient gel (7-158). (B) Autoradio- 
graph of the same gel. (C) Immunoblots of the same samples with 
PHF-specific mAb AT-S. (D) I~unoblot with mAb Tau-l . (E) Im- 
munoblot with mAb SM133. The phosphate content of the protein was 
as follows: 0 min, 9.3 mol/mol (100%); 10 min, 7.5 moVmo1 (81%); 
30 min, 5.6 mol/mol (60%); 120 min, 1.9 mol/mol (20%); 300 min, 
1.4 mollmol (15%); 16 h, 1.0 moUmo1 (11%). 
A similar picture emerges when tau protein is pre- 
phosphorylated with MAP kinase and then dephos- 
phoryfated with PP-2A (Fig. 3). While the AT8 reactiv- 
ity disappears, that of Tau-1 or SMI33 reappears upon 
dephosphorylation (Fig. 3C-E). The other phosphoryl- 
ation-dependent antibodies tested earlier with MAP ki- 
nase react in an analogous fashion (data not shown, 
compare Lichtenberg et al. 1291 with Mandelkow et al. 
[301). 
PP-2A can exist in a dimeric form, PP-ZAn, contain- 
ing the catalytic 36 kDa subunit C and the regulatory 
65 kDa subunit A. This complex can take up one of 
several other regulatory subunits, B, B’, B”, with mole- 
cular weights between 54 and 72 kDa, to form a hetero- 
trimer PP-2Ar (for review, see [6]). We wanted to test the 
efficiency of these alternative complexes and studied the 
dimeric form PP-2An and two different trimeric forms, 
PP-2AT55 and PP-2A,,,. As shown in Fig. 4A, PP-2A,,, 
was most efficient in removing the phosphates at SP or 
TP motifs; the time course of dephospho~latio~ isillus- 
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Fig. 4. Kinetics of dephospho~lation of htau40 by PP-2A, and PP- 
2A, after prior phosphorylation by MAP-kinase (phosphate content 
9.3 moles per mol). Methods were as in Figs. 1 and 2. (A) Tau was 
dephosphorylated with varying amounts of phosphatase and different 
time intervals as indicated, electrophoresed on 7-155 gradient gels 
and submitted to autor~o~aphy. The first lane shows the 
phosphorylated tau before dephosporylation. The dephosphorylation 
times (10, 30, 120 min) and phosphatase concentrations (5, 10, 20 lug 
/ml) are as indicated. (A) PP-2ALA,,, (PCS-H), (B) PP-ZAr,, (PCS-M), 
(C) PP-2An (PCS-L). (D) PP-1, catalytic subunit. Lanes 2-4: 5 @ml. 
Lanes 5-7: 10 @ml. Lanes 8-10: 20 &ml. Time course of the 
dephosphorylation with different amounts of phosphatase as indi- 
cated.(B) Time course of dephosphorylation of htau40 by PP-2A,,, as 
shown by phosphate content of samples withdrawn at the indicated 
time intervals. (C) Double reciprocal plot of the rate of the dephos- 
phorylation of htau40 by PP-2A,,, yields K,,, = 50 PM, V,,,, = 
0.6 nmoVj&min. 
0.0 0.1 0.2 0.3 0.4 0.5 0.6 
l/hTau 40 (I/'@) c 
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dimer PP-2Ao is somewhat less active (Fig. 4A, row C), 
and the other trimeric form PP-2AT72 showed a much 
lower level of phosphatase activity (Fig. 4A, row B). 
This suggests that the third subunit (B) has a strong 
influence on what type of substrate is recognized by 
PP-2A. Similar observations have been made with other 
substrates dephosphorylated at SP or TP motifs by PP- 
2A isoforms (e.g. Agostinis et al. [2]). Fig. 4C shows a 
double reciprocal plot for PP-ZA,,, with K, values for 
PP-2ATs5 and PP-2A, are in the range 25-50 PM, and 
I’,,, around 0.2-0.6 nmol/,@min. By comparison, pu- 
rified PP-1 has almost no phosphatase activity towards 
tau (Fig. 4A, row D). 
An interesting detail observed with both calcineurin 
and PP-2A is that a large fraction of the phosphate 
(about 50%) is liberated quickly within about 10 min, 
before one observes the downward shift in the gel and 
the transition from Alzheimer-like to normal antibody 
reactivity (around 30 min in Figs. 2 and 3). Since the 
shift and the antibodies are mainly sensitive to the SP 
motifs this means that the initial dephosphorylation is 
mainly due to the TP motifs. Thus it appears that the 
phosphates on TP motifs are more labile than those on 
SP motifs (similar to the preference of T over S in model 
peptides; [l]). Note that this sequence is the reverse of 
the phosphorylation reaction by MAP kinase or GSK-3 
where SP motifs tend to be phosphorylated before the 
TP motifs [17]. The experiments illustrated here were 
done with tau pre-phosphorylated with MAP kinase, 
but we note that very similar results are obtained with 
GSK-3. As shown previously [30], GSK-3 phospho- 
rylates tau less efficiently (= 4 Pi incorporated) and pre- 
fers SP motifs over TP motifs, but otherwise the 
dephosphorylation reactions by the different phos- 
phatases are comparable (data not shown). 
3.3. Dephosphorylation of tau’s microtubule binding do- 
main 
Thus far we dealt mainly with the dephosphorylation 
of phosphorylated SP and TP motifs, the ones responsi- 
ble for the Alzheimer-like antibody reactivity. However, 
these sites have only a minor influence on tau’s binding 
to microtubules. Instead, this depends mainly on the 
repeat region and in particular on S262 which is 
phosphorylated by a different kinase in brain [5] and is 
found to be phosphorylated in Alzheimer PHF tau [20]. 
We wished to know if the phosphatases affected that site 
and hence the microtubule binding. Since there are no 
diagnostic antibodies r acting with S262 we made use 
of tau construct, K18, comprising only the four repeats 
(equivalent to residues Q244-E372 in the htau40 se- 
quence). In this construct, the brain kinase activity 
phosphorylates S262 and S356 in the two IGS motifs in 
the first and fourth repeat ([5]; note that the phosphoryl- 
ation of S356 has no influence on microtubule binding). 
Fig. 5 (left) shows how the construct is phosphorylated 
by the brain extract and then dephosphorylated com- 
pletely by calcineurin and PP-2A. For comparison, the 
PP2B (Calcineurin) 
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Fig. 5. Dephosphorylation of Tau with PP-ZA,,, and PP-2B after prior phosphorylation with brain extract. hT40 and K18, a tau construct 
containing only the repeat region, were phosphorylated with extract from fresh mouse brain and brain proteins removed by boiling. The resulting 
‘2P-labeled htau40 (2.5 PM, containing 9.0 mol of phosphate per mole) or 32P-labeled K18 (8 PM, containing 2.5 mol of phosphate per mol) were 
incubated with PP-2A, (20 U/ml) and PP-2B (2 U/ml). Aliquots were withdrawn at the indicated time intervals, mixed with boiling SDS sample 
buffer and electrophoresed on 7-1596 gels. Lane 1: protein before phosphorylation; lane 2: after phosphorylation with brain extract; lane 3: 10 mm 
incubation; lane 4: 30 min; lane 5: 120 min; lane 6: 5 h; lane 7: 16 h. 
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Fig. 6. Dephosphorylation of PHFs from Alzheimer brain tissue by 
PP-A,,, and calcineurin. Lanes l-3: SDS-PAGE (silver stain); lanes 
4-6: immunoblot with antibody AT-8. Lanes 1 and 4: PHF-tau reacts 
with AT-8; lanes 2 and 5: dephosphorylation with PP-2AT,, cases a 
shift towards lower A4, and abrogates the reaction with AT-8; lanes 
3 and 6: Calcineurin has the same effects as PP-2A. 
same experiment is shown for htau40 (Fig. 5, right). 
PP-2A is more efficient than calcineurin with regard to 
the IGS motifs in the repeat domain, contrary to the SP 
or TP motifs where calcineurin is more efficient (Figs. 
1 and 2). The results show that both phosphatases act 
on all potentially ‘pathological’ phosphorylation sites of 
tau, both by proline-directed and non-proline-directed 
kinase described previously. 
3.4. Dephosphorylation of PHF-tau from Alzheimer 
brains 
In the experiments described so far we showed that 
the PHF-like phosphorylation of tau induced by MAP 
kinase or the brain extract could be removed by cal- 
cineurin or PP-2A. It remains to be shown that PHFs 
from Alzheimer brains can be dephosphorylated by the 
same phosphatases. This is demonstrated in Fig. 6. 
Dephosphorylation by calcineurin and PP-2Ar,, leads 
to a shift of the tau isoforms towards a lower M, (lanes 
2, 3) and the reactivity with PHF-specific antibody AT- 
8 disappears (lanes 5, 6). 
4. DISCUSSION 
The phosphorylation and dephosphorylation of 
MAPS has been studied by a number of authors since 
this appeared to regulate microtubule assembly. Several 
protein kinases were able to phosphorylate tau, and in 
studying the reverse process it was reported that cal- 
cineurin and PP-2A were particularly active in dephos- 
phorylating MAPS such as MAP2 and tau ([14,31,39]; 
for review, see [23]). A question not resolved by these 
earlier studies was the nature of the phosphorylation 
sites, and which sites were targeted by particular kinases 
and phosphatases. These issues became relevant for 
Alzheimer’s disease research when it was discovered 
that tau was the main protein of Alzheimer PHFs, and 
that this protein was abnormally phosphorylated (for 
review, see [27]). 
After tau was cloned and sequenced [11,12,26] it be- 
came possible to identify phosphorylation sites and epi- 
topes of antibodies which were sensitive to phosphoryl- 
ation. This led to the determination of the sites several 
kinases (PKA [5,33]; PKC [8]; CaMK [34]; cdc2 [25,36]). 
Of particular interest was the fmding that certain ki- 
nases transformed tau into an ‘Alzheimer-like’ state, as 
judged by the reaction with diagnostic antibodies [4,29]. 
These kinases were present in normal brains, 
phosphorylated SP and TP motifs and thus belonged to 
the family of proline-directed kinases [17]. Kinases of 
this type were MAP kinase [lo], GSK-3 [18,22,30] cdk2 
and cdk5 [41]. Another type of ‘pathological’ phospho- 
rylation was that of S262 which was observed in PHFs 
[20] and strongly reduced the interaction with microtu- 
bules, in contrast to the proline-directed kinases [5]. 
In this report we have used our previous knowledge 
about phosphorylation sites, antibody epitopes, and ki- 
nases to ask which of the ‘abnormal’ sites are kept 
unphosphorylated in a normal brain. In other words, 
since phosphorylation results from a competition be- 
tween kinases and phosphatases, and since the kinases 
affecting the ‘abnormal’ sites were present in normal 
brain, the corresponding phosphatases have to be pres- 
ent as well. We therefore studied the phosphatase activ- 
ity in brain extract by selective inhibitors, and compared 
this with purified phosphatases. SP or TP motifs were 
first phosphorylated with MAP kinase (or GSK-3), and 
their dephosphorylation monitored by autoradiography 
and phosphorylation dependent antibodies. In the case 
of S262 the state of phosphorylation was monitored by 
comparing constructs that had no SP or TP motifs (such 
as K18), since antibodies specific for that site were not 
available. 
We conclude that both types of abnormal phospho- 
rylation sites can be dephosphorylated by calcineurin 
and PP-2A, with the trimeric form PP-2Arss (alias PP- 
2A,, PCS-H) being the more active than other trimeric 
or dimeric forms (PP-2A,,z = PCS-M, PP-2An = PP- 
2A, = PCS-L, Fig. 4). This suggests a strong regulatory 
function of the B subunit of PP-2A. By contrast, PP-1 
is inactive. These results are based on the experiments 
with purified phosphatases. However, in the brain ex- 
tract, calcineurin appears to be the more active phos- 
phatase. 











PP - 2A 
“S262” Kinase - s262 
Fig. 7. Diagram showing the two types of abnormal phosphorylation 
sites on tau protein (S/T-P or S262), the kinases phosphorylating these 
sites (MAP kinase/GSK-3 or S262 kinase), and the two phosphatases 
calcineurin and PP-2A which counteract he phosphorylation of these 
sites. 
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previously [ 171 that phosphorylation of tau by the brain 
extract (containing the endogenous MAP kinase, GSK- 
3, and other kinases) was possible only by inhibiting the 
phosphatases with the Ca” chelator EGTA and with 
okadaic acid. EGTA was more important than OA; 
EGTA alone allowed phosphorylation of tau up to 4 Pi, 
OA alone had no effect (no phosphorylation since the 
phosphatase activity was too high), EGTA plus OA 
allowed a somewhat higher phosphorylation than 
EGTA alone (5 Pi). These results argue that calcineurin 
is the main antagonist of MAP kinase or GSK-3 in the 
brain extract. 
In this paper we started from defined initial condi- 
tions since we phosphorylated tau first by purified MAP 
kinase and then observed the activity of the brain ex- 
tract (Fig. 1). With no inhibitors added, the phosphates 
were removed quickly; EGTA was completely inhib- 
itory, while OA even at PM concentrations was only 
partially inhibitory. Our interpretation is again that cal- 
cineurin is the predominant phosphatase of the sites 
targeted by MAP kinase. When calcineurin is inhibited 
by EGTA, neither PP-1 (which is inactive anyway to- 
wards tau, see above) nor PP-2A can dephosphorylate 
tau. When PP-2A is inhibited by OA at sub-PM levels, 
there is still full phosphatase activity. It takes OA levels 
around 10 ,uM to observe partial inhibition. We sus- 
pected earlier [ 171 that his would point to a role of PP- 1 
(since PP-1 requires higher concentrations of OA for 
inhibition than PP-2A), but we note now that this may 
well be due to the partial inhibition of calcineurin by 
OA since the I&, concentration is about 5 ,uM [3]. 
The question of phosphatases that remove the MAP 
kinase target sites from tau has been addressed by Goe- 
dert et al. [13]. They concluded that PP-1 was inactive 
and PP-2A was active, in agreement with our observa- 
tions. However, they found calcineurin to be ineffective 
as a phosphatase, in contrast to our conclusions. Other 
authors had studied more generally the dephosphoryla- 
tion of MAPS such as MAP2 or tau which share a 
similar protein character and microtubule binding re- 
gion [28]. For example, Goto et al. [14] reported on the 
MAP-phosphatase activity of calcineurin, and 
Yamamoto et al. [39] described similar results for PP- 
2A. Since the protein sequences and phosphorylation 
sites were not known at the time the data could not be 
interpreted in detail. Now we know that these two 
phosphatases act as scavengers to keep sites clean that 
might otherwise appear as phatological sites in ageing 
neurons. There are, however, differences in efficiency: 
PP-2A acts more rapidly than calcineurin on the 
phosphorylated IGS motifs in the repeat region, while 
the opposite is true for the SP or TP motifs. 
Finally, we note that calcineurin and PP-2A also act 
on PHF-tau isolated from Alzheimer brains. The phos- 
phorylation sites of PHF-tau have been partially 
mapped, they include Seti62 and several SP or TP motifs 
[20,32]. Thus the phosphorylation state resembles that 
achieved by the experiments with brain extract [ 171 and 
explains why the same phosphatases can dephospho- 
rylate PHFs. A similar state of phosphorylation can be 
achieved in situ by incubating brain slices with OA; 
here, too, the effect can be reversed primarily by cal- 
cineurin [19]. 
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